ARS Pharmaceuticals

Needle-Free Allergy Therapies Will Capture Untapped Global Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

25 Aug 25

Updated

25 Aug 25

AnalystHighTarget's Fair Value

US$40.00

66.4% undervalued

25 Aug

US$13.44

-2.2%

-7.9%

-2.2%

-7.9%

Author's Valuation

US$40.0

66.4% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$40.0

66.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

42.21%

Biotech revenue growth rate

11.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$112.89m

Earnings '28

44.43x

PE Ratio '28

US$5.02b

Market Cap '28

US$5.02b

Market Cap '28

103.92m

No. shares '28

US$48.26

Share Price '28

US$48.26 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$39.65

Fair Value '25